Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California with a unique ability to rapidly engineer, optimize and manufacture superior, high-fidelity vaccines at scale. We do this by re-engineering how highly complex vaccines are made, using advanced chemistry and modern synthetic techniques - including the XpressCF cell-free protein synthesis platform - to create difficult-to-make proteins that deliver enhanced immunological benefits. Our lead clinical candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) to treat invasive pneumococcal disease and pneumonia currently being investigated in a Phase 1/2 proof-of-concept study in adults. We are pursuing a clear strategy for our PCV franchise, which leverages a known regulatory pathway established by already approved PCVs.